Hot Products

Bruceine D
Catalog No: CFN90771

Bruceine D has anti-cancer activity, it inhibits the growth of three pancreatic cancer cell lines, i.e., PANC-1, SW1990 and CAPAN-1; induces cytotoxicity in Capan-2 cells via the induction of cellular apoptosis involving the mitochondrial pathway.Bruceine D may have the potential to be used as a natural viricide, or a lead compound for new viricides.

Bruceine E
Catalog No: CFN89340

Bruceine E exhibits significant blood glucose concentration reduction activity, it might act as an insulin secretagogue.

Bruceine J
Catalog No: CFN91973

Reference standards.

Brucine
Catalog No: CFN90244

Brucine has anti-cncer activity, it can treat hepatocellular carcinoma (HCC) and inhibit the proliferation of human lung cancer cell line PC-9 mainly by blocking the cell cycle at G0/G1 via down-regulating the expression of Cyclin D1, Cyclin E.

Brucine sulfate
Catalog No: CFN90316

Brucine sulfate is a product from Strychnos nux-vomica L.

Brusatol
Catalog No: CFN93119

Brusatol, a Nrf2 inhibitor, has dual anti-hepatitis C virus and anticancer effects and can enhance the comparable effects of sorafenib. Brusatol-mediated inhibition of c-Myc/ROS signaling pathway increases HIF-1α degradation by promoting PHD activity and induces cell death in colorectal cancer under hypoxia. It inhibits the response of cultured beta-cells to pro-inflammatory cytokines in vitro. Brusatol also shows antitrypanosomal activity against trypomastigotes of Trypanosoma evansi.

BR-Xanthone A
Catalog No: CFN99224

Reference standards.

Bryonolic acid
Catalog No: CFN98260

Bryonolic acid has cytotoxic, anti-allergic, anti-inflammatory and antioxidant activities, it can reduce the inflammatory mediator NO by suppressing the expression of the inflammatory enzyme inducible nitric oxide synthase (iNOS) in LPS-activated RAW 264.7 macrophage cells. Bryonolic acid may be a promising neuroprotective agent for the treatment of cerebral ischemia disease, it can protect PC12 cells against NMDA-induced apoptosis by inhibiting Ca2+ influx and regulating gene expression in the Ca2+-CaMKII-CREB signal pathway.

Bryonolol
Catalog No: CFN90562

Reference standards.

Buddlejasaponin IV
Catalog No: CFN98519

Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation. Buddlejasaponin IV exerts cytotoxic effects against cancer cells,it can induce cell cycle arrest at G2/M phase and apoptosis in immortalized human oral keratinocytes, it may possess antimetastatic potential by inducing anoikis and upregulating NAG-1 expression. Buddlejasaponin IV can inhibit intrinsic and extrinsic hyperlipidemia and hypercholesterolemia in the rat.